Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department holds on the number of children and young people with cancer from Scotland who have received some or all of their treatment in England within the last five years; and whether his Department provides support for travel costs for those patients.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to putting patients first and providing speedy and high-quality care, irrespective of where patients are treated in United Kingdom. The Department of Health and Social Care (DHSC) works collaboratively with the Devolved Governments to drive forward its objective of supporting people, including children and young people with cancer, to lead more independent, healthier lives for longer.
DHSC knows that the cost of travel is an important issue for many young cancer patients and their families in England.
The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the UK who provide support, including financial support, for patients with cancer.
On 4 February 2025, DHSC relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients in England. The taskforce will ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve experience and outcomes for children and young people with cancer in England.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure equity of access to cancer treatment and care for children and young people with cancer from Scotland who may receive some or all of their care in England; and what recent discussions he has had with the Scottish Government on this matter.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to putting patients first and providing speedy and high-quality care, irrespective of where patients are treated in United Kingdom. The Department of Health and Social Care (DHSC) works collaboratively with the Devolved Governments to drive forward its objective of supporting people, including children and young people with cancer, to lead more independent, healthier lives for longer.
DHSC knows that the cost of travel is an important issue for many young cancer patients and their families in England.
The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the UK who provide support, including financial support, for patients with cancer.
On 4 February 2025, DHSC relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients in England. The taskforce will ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve experience and outcomes for children and young people with cancer in England.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of introducing a fund to support children and young people with cancer with the costs of travelling to specialist treatment centres through the development of the National Cancer Plan for England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to putting patients first and providing speedy and high-quality care, irrespective of where patients are treated in United Kingdom. The Department of Health and Social Care (DHSC) works collaboratively with the Devolved Governments to drive forward its objective of supporting people, including children and young people with cancer, to lead more independent, healthier lives for longer.
DHSC knows that the cost of travel is an important issue for many young cancer patients and their families in England.
The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the UK who provide support, including financial support, for patients with cancer.
On 4 February 2025, DHSC relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients in England. The taskforce will ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve experience and outcomes for children and young people with cancer in England.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department will commit to publishing regular data on leukaemia diagnosis delays and outcomes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Disease Registration Service collects information on how many people in England are diagnosed with or treated for cancer. Blood cancer is included as a distinct category, labelled haematological neoplasms, with further information avaiable at the following link:
https://nhsd-ndrs.shinyapps.io/incidence_and_mortality/
This creates a clinically rich data resource that is used to measure diagnosis, treatment, and outcomes for patients diagnosed with cancer.
The 28-day faster diagnosis standard is a performance standard that aims to have a patient diagnosed with or have cancer ruled out within 28-days from referral. This performance metric monitors diagnostic performance and delays in diagnosis across cancer types, including leukaemia. It is published monthly and can be found at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Data is collected on cancer survival, with the most recent dataset being published in February 2023, which provides survival data from 2016 to 2020, followed up to 2021. The next publication will be released soon and will provide data on cancer survival diagnosed from 2018 to 2022 followed up to 2023. The survival datasets can be found at the following link:
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to his Department's guidance entitled Independent review into mental health conditions, ADHD and autism, published on 4 December 2025, what steps he will take to (a) engage and (b) consult with (i) children and (ii) parents with lived experience.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that the independent review into mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism reflects the voices of those with lived experience.
As stated in the terms of reference published on the GOV.UK website, the independent review will work closely with people with lived experience of mental health conditions, ADHD, and autism across different age groups, including young people, and reflect under-represented groups. It will also consult closely with parents and carers, key partners, and wider clinical and academic experts as appropriate. The terms of reference are available at the following link:
The review Chair and Vice-Chairs are currently developing their approach to engaging with lived experience groups.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of the use of the drug Vorasidenib to manage the symptoms and progression of low grade Glioma.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
While the Department has made no assessment, the National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS on the basis of an assessment of clinical and cost effectiveness. NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over.
The draft guidance was shared with all stakeholders as well as being published on the NICE website for public comment as part of the consultation which took place between 15 October and 4 November 2025. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expect to publish final guidance in January 2026.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking with Cabinet colleagues on improving support for unpaid carers.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Supporting unpaid carers is a cross-Government issue which requires cross-Government support. I recently met with the Parliamentary Under-Secretary of State for Employment Rights, Competition and Markets in the Department for Business and Trade and the Minister of State for Social Security and Disability in the Department for Work and Pensions to look at how we can work together more closely to support unpaid carers.
The Government has already taken steps to support unpaid carers. From April 2025, we are increasing the Carer's Allowance weekly earnings limit from £151 a week to £196. This means carers can earn up to £10,000 a year whilst still retaining Carer's Allowance; this is approximately an additional £2,000 a year.
The Government recognises the challenges facing the adult social care system. That is why the Government is launching an independent commission into adult social care as part of our critical first steps towards delivering a National Care Service.
The commission will start a national conversation about what working age adults, older people, and their families expect from adult social care, including exploring the needs of unpaid carers who provide vital care and support.
The Government is also committed to reviewing the implementation of Carer’s Leave and examining the benefits of introducing paid Carer’s Leave.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that the cross-government delivery plan for ME/CFS establishes a common UK-wide approach.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The final delivery plan for myalgic encephalomyelitis, also known as chronic fatigue syndrome, will cover the population of England only.
However, due to the United Kingdom-wide nature of this issue, we have maintained engagement with the devolved administrations during the analysis of the consultation responses on the interim delivery plan, as well as on the ongoing development of the final plan.
We will continue to work closely with those devolved administrations to ensure that policy development and learning across the UK’s nations is shared.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress his Department has made on allocating funding to brain cancer research.
Answered by Andrew Gwynne
Research is crucial in tackling cancer, which is why the Department invests over £1.5 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group, reflecting its high priority. We are committed to furthering our investment and support for high-quality brain tumour research.
In the five years between 2018/19 and 2022/23, the NIHR directly invested £11.3 million in research projects and programmes focused on brain tumours across 15 awards. In addition, our wider investments in NIHR research infrastructure, including facilities, services, and the research workforce, are estimated to be £31.5 million, between 2018/19 and 2022/23, and have enabled 227 brain cancer research studies to take place in the same period. In total NIHR investments have enabled 8,500 people to participate in potentially life-changing research in the National Health Service over this time.
In September 2024, the NIHR launched new funding opportunities for a Brain Cancer Research Consortium and a major new funding call to generate high quality evidence in brain tumour care, support, and rehabilitation.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact on human health of updating the Clean Air Act 1993 in line with World Health Organisation air quality guidelines published in 2021.
Answered by Andrew Gwynne
The Government is committed to cleaning up our air and protecting the public from the harms of pollution and plans to introduce a comprehensive Clean Air Strategy which will include a series of interventions to reduce emissions, and in turn everyone’s exposure to air pollution.
There are currently no plans to undertake a general assessment of the potential impact on human health given that it is already well established that even low concentrations of air quality pollutants are likely to be associated with adverse effects on health. Therefore, continued reductions, even where concentrations are below the air quality guidelines, are likely to be beneficial to health.